$CHRS: Coherus Reports Positive Interim Clinical Data for Tagmokitug in Esoph

$CHRS

$CHRS – Coherus Reports Positive Interim Clinical Data for Tagmokitug in Esophageal Cancer

Coherus Oncology, Inc.

2026-10-29 00:00:00 UTC · SEC_8K · All $CHRS

?? Positive AI Sentiment (+6.8 / 10)

Phase interim data shows 75% cORR in 1L ESCC across all-comers and up to 89% post-cutoff, with 100% in PD-L1-positive patients.
Exceeds standard-of-care historical benchmarks (44%-59% cORR for PD-L1-positive ESCC).
Grade 3-5 immune-related adverse events observed in 20% of patients across safety cohort.